The BRCA2 p.C1200 mutation, linked to homologous recombination deficiency (HRD), suggests that the patient may respond to PARP inhibitors (33, 34), which target cells deficient in DNA repair. The gene discussed is BRCA2; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.